Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Trevena Inc.
DescriptionG protein-biased mu opioid receptor (OPRM1; MOR) ligand
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationPain
Indication DetailsTreat moderate to severe acute and chronic pain
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today